Mirum Pharmaceuticals (MIRM) Raw Materials (2021 - 2026)

Mirum Pharmaceuticals' Raw Materials history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 13.68% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 13.68% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 4.36% from the prior year.
• Raw Materials slipped to $2.6 million in Q1 2026 per MIRM's latest filing, from $2.9 million in the prior quarter.
• Across five years, Raw Materials topped out at $3.0 million in Q4 2024 and bottomed at $444000.0 in Q3 2023.
• The 5-year median for Raw Materials is $2.9 million (2024), against an average of $2.5 million.
• Across the five-year window, Raw Materials soared 528.38% in 2024 and retreated 13.68% in 2026, its largest moves.
• Year by year, Raw Materials stood at $858000.0 in 2022, then surged by 249.42% to $3.0 million in 2023, then climbed by 1.07% to $3.0 million in 2024, then declined by 4.36% to $2.9 million in 2025, then declined by 9.87% to $2.6 million in 2026.
• Per Business Quant, the three latest MIRM Raw Materials figures stand at $2.6 million (Q1 2026), $2.9 million (Q4 2025), and $2.9 million (Q3 2025).